Illumina Inc. (NASDAQ:ILMN) has been experiencing a myriad of financial fluctuations recently. It seems the company has exceeded Q2 Earnings and Revenues estimates, which prompted a price target increase to $124.00, and later to $133.00 and $155.00, signifying a strong financial performance. Other notable events include the launch of a new oncology menu for NovaSeq X Series customers and acquisition of Fluent BioSciences, aiming to accelerate single-cell analysis and discovery. Illumina's consistent performance led to an
Outperform Rating from the Royal Bank of Canada and a
Buy upgrade from Citigroup. Notably, Wall Street analysts suggest Illumina could surge 27.02%. However, Q3 2024 EPS estimates decreased. Illumina has recently completed a spin-off of GRAIL, and there's a notable increase in their position by the Mather Group LLC., while Park Avenue Securities LLC and Sei Investments Co. also increased their shares. On the other hand, the planned divestiture of GRAIL led to a significant loss. Institutional shareholders hold 90% of the company, with Jacob Thaysen, Illumina CEO, purchasing 7,330 shares, showing strong belief in the company.
Illumina ILMN News Analytics from Mon, 13 Nov 2023 08:00:00 GMT to Sun, 11 Aug 2024 16:10:03 GMT -
